Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Lupin Q1 Preview: Healthy US sales, favourable base to lift earnings
Lupin Q1 PAT may dip 73.3% YoY to Rs 144.7 cr: ICICI Direct
Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher
Lupin Q4 PAT may dip 49.9% YoY to Rs 230.5 cr: Prabhudas Lilladher
Lupin Q2 PAT seen up 33.1% YoY to Rs 280.9 cr: Prabhudas Lilladher
Lupin Q1 PAT seen up 258.7% YoY to Rs 389.9 cr: KRChoksey
Lupin Q1 PAT seen up 474% YoY to Rs 613.6 cr: ICICI Direct
LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan
Lupin Q2 Preview: Adjusted profit may decline sharply on subdued revenue, operating performance
Lupin Q4 FY20 results: Key highlights of concall
Lupin Q4 preview: Double-digit decline seen in profit, revenue
Lupin widens losses in Q3; highlights of conference call
Lupin Q2 preview: Profit may grow in double-digits on better operating income
Lupin Q2 PAT may dip 22% YoY to Rs. 206.5 cr: Emkay
Lupin Q1 PAT seen up 17.6% YoY to Rs. 296.5 cr: Prabhudas Lilladher
Lupin Q4 preview: Net profit likely to fall, EBITDA margin to take a hit
Lupin Q4 PAT may dip 62.8% YoY to Rs. 253.2 cr: Prabhudas Lilladher
Lupin Q3 PAT seen up 20.7% YoY to Rs. 267.1 cr: ICICI Direct
Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila
Lupin Q2 preview: Weakness in US business to hurt, say experts
Lupin Q2 PAT may dip 59.1% YoY to Rs. 190 cr: HDFC Securities
Lupin Q2 PAT may dip 34% YoY to Rs. 299 cr: Sharekhan
Lupin Q2 PAT may dip 51.2% YoY to Rs. 222.2 cr: ICICI Direct
Lupin Q1 PAT may dip 2.9% YoY to Rs. 347.5 cr: Kotak
Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Lupin Q1 Preview: Healthy US sales, favourable base to lift earnings

Lupin Q1 PAT may dip 73.3% YoY to Rs 144.7 cr: ICICI Direct

Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher

Lupin Q4 PAT may dip 49.9% YoY to Rs 230.5 cr: Prabhudas Lilladher

Lupin Q2 PAT seen up 33.1% YoY to Rs 280.9 cr: Prabhudas Lilladher

Lupin Q1 PAT seen up 258.7% YoY to Rs 389.9 cr: KRChoksey

Lupin Q1 PAT seen up 474% YoY to Rs 613.6 cr: ICICI Direct

LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan

Lupin Q2 Preview: Adjusted profit may decline sharply on subdued revenue, operating performance

Lupin Q4 FY20 results: Key highlights of concall

Lupin Q4 preview: Double-digit decline seen in profit, revenue

Lupin widens losses in Q3; highlights of conference call

Lupin Q2 preview: Profit may grow in double-digits on better operating income

Lupin Q2 PAT may dip 22% YoY to Rs. 206.5 cr: Emkay

Lupin Q1 PAT seen up 17.6% YoY to Rs. 296.5 cr: Prabhudas Lilladher

Lupin Q4 preview: Net profit likely to fall, EBITDA margin to take a hit

Lupin Q4 PAT may dip 62.8% YoY to Rs. 253.2 cr: Prabhudas Lilladher

Lupin Q3 PAT seen up 20.7% YoY to Rs. 267.1 cr: ICICI Direct

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

Lupin Q2 preview: Weakness in US business to hurt, say experts

Lupin Q2 PAT may dip 59.1% YoY to Rs. 190 cr: HDFC Securities

Lupin Q2 PAT may dip 34% YoY to Rs. 299 cr: Sharekhan

Lupin Q2 PAT may dip 51.2% YoY to Rs. 222.2 cr: ICICI Direct

Lupin Q1 PAT may dip 2.9% YoY to Rs. 347.5 cr: Kotak

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz